PubMed Journals Articles About "ERSPC European Randomized Study Screening Prostate Cancer" RSS

16:11 EDT 17th October 2018 | BioPortfolio

ERSPC European Randomized Study Screening Prostate Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest ERSPC European Randomized Study Screening Prostate Cancer articles that have been published worldwide.

More Information about "ERSPC European Randomized Study Screening Prostate Cancer" on BioPortfolio

We have published hundreds of ERSPC European Randomized Study Screening Prostate Cancer news stories on BioPortfolio along with dozens of ERSPC European Randomized Study Screening Prostate Cancer Clinical Trials and PubMed Articles about ERSPC European Randomized Study Screening Prostate Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ERSPC European Randomized Study Screening Prostate Cancer Companies in our database. You can also find out about relevant ERSPC European Randomized Study Screening Prostate Cancer Drugs and Medications on this site too.

Showing "ERSPC European Randomized Study Screening Prostate Cancer" PubMed Articles 1–25 of 78,000+

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

The Influence of decision aids on prostate cancer screening preferences: A randomized survey study.

Shared decision making is recommended regarding prostate cancer screening. Decision aids may facilitate this process; however, the impact of decision aids on screening preferences is poorly understood.

Predictors of participation in risk-based prostate cancer screening.

Implementation of risk-based prostate cancer screening has been proposed as a means to reduce the harms of PSA screening. Little is known, however, about the factors influencing men's decision to attend a prostate cancer screening based on a risk assessment.

Overdiagnosis in Colorectal Cancer Screening - Time to Acknowledge A Blind Spot.

Overdiagnosis is recognized as a major harm of mammography screening for breast cancer and prostate cancer screening with prostate-specific-antigen (PSA). Colorectal cancer screening is being more broadly implemented in many countries, and screening rates are increasing steadily. Surprisingly, there is a striking and almost complete lack of knowledge about overdiagnosis in colorectal cancer screening. Overdiagnosis is not part of patient information material, hardly mentioned in guidelines, and not addresse...

New Evidence for the Benefit of PSA Screening: Data From 400,887 Kaiser Permanente Patients.

To investigate whether prostate cancer screening with PSA is beneficial in reducing prostate cancer mortality, and to determine optimal screening intervals and age groups to be screened.

Personalized Prostate Cancer Screening Based on a Single Midlife Prostate-specific Antigen Measurement.

Modelling human prostate cancer: Rat models.

Prostate cancer is the second most common cancer in men, affecting approximately 1.1 million men worldwide. In this way, the study of prostate cancer biopathology and the study of new potential therapies is of paramount importance. Several rat models were developed over the years to study prostate cancer, namely spontaneous models, chemically-induced models, implantation of cancer cell lines and genetically-engineered models. This manuscript aimed to provide the readers with an overview of the rat models of...

Evaluating a psychosocial intervention for men with prostate cancer and their partners: Outcomes and lessons learned from a randomized controlled trial.

This study evaluated the process and outcome of a psychosocial intervention for men with prostate cancer and their partners. As more men survive prostate cancer, they and their partners need help and support to help them cope with the physical and psychosocial effects of the disease and treatment. There is a lack of psychosocial interventions for men with prostate cancer and their partners.

Breast cancer screening : present situation and prospects.

Breast cancer screening is a public health challenge. Belgium has the worldwide highest age-standardized breast cancer incidence. It ranks third in terms of specific mortality. The causes are unclear and presumably multifactorial. Like most European countries, Belgium has set up a screening program since 2001. Despite coverage rates varying from one Region to another, the annual 2 % specific mortality decline (observed in the vast majority of European countries) is the same. The age-based screening programs...

An Update on the European Lung Cancer Screening Trials and Comparison of Lung Cancer Screening Recommendations in Europe.

While lung cancer screening has been implemented in the United States, it is still under consideration in Europe. So far, lung cancer screening trials in Europe were not able to replicate the results of the National Lung Screening Trial, but they do show a stage shift in the lung cancers that were detected. While eagerly awaiting the final result of the only lung cancer screening trial with sufficient statistical power, the NELSON trial, a number of European countries and medical societies have published re...

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.

We tested whether intervention with atorvastatin affects the prostate beneficially compared with placebo in men with prostate cancer in a randomized clinical trial. A total of 160 statin-naïve prostate cancer patients scheduled for radical prostatectomy were randomized to use 80mg atorvastatin or placebo daily from recruitment to surgery for a median of 27 d. Blinding was maintained throughout the trial. In total, 158 men completed the follow-up, with 96% compliance. Overall, atorvastatin did not significa...

A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.

When some individuals are screen-detected before the beginning of the study, but otherwise would have been diagnosed symptomatically during the study, this results in different case-ascertainment probabilities among screened and unscreened participants, referred to here as lead-time-biased case-ascertainment (LTBCA). In fact, this issue can arise even in risk-factor studies nested within a randomized screening trial; even though the screening intervention is randomly allocated to trial arms, there is no ran...

Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer.

Prostate-specific antigen (PSA) is central in the diagnosis of prostate cancer. However, high-quality biological variation (BV) estimates for PSA are scarce. Here BV estimates from the European Biological Variation Study (EuBIVAS) for total (tPSA), free (fPSA), conjugated PSA (cPSA), and percent free PSA (%fPSA) are provided.

The legal framework for European cervical cancer screening programmes.

A comprehensive legal framework needs to be developed to run the health services and to regulate the information systems required to manage and to ensure the quality of cancer screening programmes. The aim of our study was to document and to compare the status of legal basis for cervical screening registration in European countries.

Mortality From Post-screening (Interval) Colorectal Cancers is Comparable to That From Cancer in Unscreened Patients-a Randomized Sigmoidoscopy Trial.

Endoscopic screening for colorectal cancer (CRC) is performed at longer time intervals than the fecal occult blood test or screens for breast or prostate cancer. This causes concerns about interval cancers, which have been proposed to progress more rapidly. We compared outcomes of patients with interval CRCs after sigmoidoscopy screening vs outcomes of patients with CRC who had not been screened.

Current guidelines for prostate cancer screening: A systematic review and minimal core proposal.

Considering the importance of screening for prostate cancer, the possibility of damage resulting from indiscriminate screening and the difficulty of disclosure and adherence to the main guidelines on the subject, we aimed to identify current guidelines, look for common approaches and establish a core of conducts.

Male Oncology Research and Education program for men at high risk for prostate cancer.

Three groups of men are at high risk of developing prostate cancer: men with a strong family history of prostate cancer, men of West African or Caribbean ancestry, and men with a germline pathogenic variant in a prostate cancer-associated gene. Despite the fact that those men constitute a significant portion of the male population in North America, few recommendations for prostate cancer screening specific to them have been developed. For men at general population risk for prostate cancer, screening based o...

Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population.

Prostate cancer is one of the most commonly diagnosed malignancies among men in Western populations. Evidence reported in the literature suggests that zinc may be related to prostate cancer. In this study we evaluated the association of serum zinc levels and polymorphisms in genes encoding zinc-dependent proteins with prostate cancer in Poland.

Association Between Online Information-Seeking and Adherence to Guidelines for Breast and Prostate Cancer Screening.

From 2012 through 2014, the US Preventive Services Task Force (USPSTF) recommended biennial mammography for women aged 50 to 75 and recommended against the prostate specific antigen (PSA) test for men of any age, emphasizing informed decision making for patients. Because of time constraints and other patient health priorities, health care providers often do not discuss benefits and risks associated with cancer screening. We analyzed the association between seeking information online about breast and prostat...

Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.

Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer. In the present study, we explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.

Quick Search